Literature DB >> 29073114

Pathogenesis of hypothyroidism-induced NAFLD is driven by intra- and extrahepatic mechanisms.

Giuseppe Ferrandino1, Rachel R Kaspari1, Olga Spadaro2, Andrea Reyna-Neyra1, Rachel J Perry3, Rebecca Cardone3, Richard G Kibbey1,3, Gerald I Shulman1,3,4, Vishwa Deep Dixit2,5,6, Nancy Carrasco7.   

Abstract

Hypothyroidism, a metabolic disease characterized by low thyroid hormone (TH) and high thyroid-stimulating hormone (TSH) levels in the serum, is strongly associated with nonalcoholic fatty liver disease (NAFLD). Hypothyroidism-induced NAFLD has generally been attributed to reduced TH signaling in the liver with a consequent decrease in lipid utilization. Here, we found that mildly hypothyroid mice develop NAFLD without down-regulation of hepatic TH signaling or decreased hepatic lipid utilization. NAFLD was induced by impaired suppression of adipose tissue lipolysis due to decreased insulin secretion and to a reduced response of adipose tissue itself to insulin. This condition leads to increased shuttling of fatty acids (FAs) to the liver, where they are esterified and accumulated as triglycerides. Lipid accumulation in the liver induces hepatic insulin resistance, which leads to impaired suppression of endogenous glucose production after feeding. Hepatic insulin resistance, synergistically with lowered insulin secretion, increases serum glucose levels, which stimulates de novo lipogenesis (DNL) in the liver. Up-regulation of DNL also contributes to NAFLD. In contrast, severely hypothyroid mice show down-regulation of TH signaling in their livers and profound suppression of adipose tissue lipolysis, which decreases delivery of FAs to the liver. The resulting lack of substrates for triglyceride esterification protects severely hypothyroid mice against NAFLD. Our findings demonstrate that NAFLD occurs when TH levels are mildly reduced, but, paradoxically, not when they are severely reduced. Our results show that the pathogenesis of hypothyroidism-induced NAFLD is both intra- and extrahepatic; they also reveal key metabolic differences between mild and severe hypothyroidism. Published under the PNAS license.

Entities:  

Keywords:  NAFLD; de novo lipogenesis; hypothyroidism; insulin resistance; sodium/iodide symporter

Mesh:

Substances:

Year:  2017        PMID: 29073114      PMCID: PMC5664516          DOI: 10.1073/pnas.1707797114

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  50 in total

1.  Effects of thyroid function upon insulin secretion.

Authors:  W J Malaisse; F Malaisse-Lagae; E F McCraw
Journal:  Diabetes       Date:  1967-09       Impact factor: 9.461

2.  Non-alcoholic fatty liver disease across the spectrum of hypothyroidism.

Authors:  Goh Eun Chung; Donghee Kim; Won Kim; Jeong Yoon Yim; Min Jung Park; Yoon Jun Kim; Jung-Hwan Yoon; Hyo-Suk Lee
Journal:  J Hepatol       Date:  2012-03-14       Impact factor: 25.083

Review 3.  Failure of fat cell proliferation, mitochondrial function and fat oxidation results in ectopic fat storage, insulin resistance and type II diabetes mellitus.

Authors:  L Heilbronn; S R Smith; E Ravussin
Journal:  Int J Obes Relat Metab Disord       Date:  2004-12

Review 4.  The Biochemistry and Physiology of Mitochondrial Fatty Acid β-Oxidation and Its Genetic Disorders.

Authors:  Sander M Houten; Sara Violante; Fatima V Ventura; Ronald J A Wanders
Journal:  Annu Rev Physiol       Date:  2015-10-14       Impact factor: 19.318

5.  Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease.

Authors:  Kerry L Donnelly; Coleman I Smith; Sarah J Schwarzenberg; Jose Jessurun; Mark D Boldt; Elizabeth J Parks
Journal:  J Clin Invest       Date:  2005-05       Impact factor: 14.808

6.  Identification of novel phosphorylation sites in hormone-sensitive lipase that are phosphorylated in response to isoproterenol and govern activation properties in vitro.

Authors:  M W Anthonsen; L Rönnstrand; C Wernstedt; E Degerman; C Holm
Journal:  J Biol Chem       Date:  1998-01-02       Impact factor: 5.157

Review 7.  Thyroid disease and the heart.

Authors:  Irwin Klein; Sara Danzi
Journal:  Circulation       Date:  2007-10-09       Impact factor: 29.690

Review 8.  Thyroid hormone regulation of metabolism.

Authors:  Rashmi Mullur; Yan-Yun Liu; Gregory A Brent
Journal:  Physiol Rev       Date:  2014-04       Impact factor: 37.312

9.  Dissociation of inositol-requiring enzyme (IRE1α)-mediated c-Jun N-terminal kinase activation from hepatic insulin resistance in conditional X-box-binding protein-1 (XBP1) knock-out mice.

Authors:  Michael J Jurczak; Ann-Hwee Lee; Francois R Jornayvaz; Hui-Young Lee; Andreas L Birkenfeld; Blas A Guigni; Mario Kahn; Varman T Samuel; Laurie H Glimcher; Gerald I Shulman
Journal:  J Biol Chem       Date:  2011-11-28       Impact factor: 5.157

10.  Thyroid Hormone Regulates the mRNA Expression of Small Heterodimer Partner through Liver Receptor Homolog-1.

Authors:  Hwa Young Ahn; Hwan Hee Kim; Ye An Kim; Min Kim; Jung Hun Ohn; Sung Soo Chung; Yoon Kwang Lee; Do Joon Park; Kyong Soo Park; David D Moore; Young Joo Park
Journal:  Endocrinol Metab (Seoul)       Date:  2015-10-20
View more
  11 in total

1.  The paradoxical lean phenotype of hypothyroid mice is marked by increased adaptive thermogenesis in the skeletal muscle.

Authors:  Rachel R Kaspari; Andrea Reyna-Neyra; Lara Jung; Alejandra Paola Torres-Manzo; Sandro M Hirabara; Nancy Carrasco
Journal:  Proc Natl Acad Sci U S A       Date:  2020-08-21       Impact factor: 11.205

2.  Severe Phenotype of Non-alcoholic Fatty Liver Disease in Pediatric Patients with Subclinical Hypothyroidism: a Retrospective Multicenter Study from Korea.

Authors:  So Yoon Choi; Dae Yong Yi; Soon Chul Kim; Ben Kang; Byung Ho Choe; Yoon Lee; Yoo Min Lee; Eun Hye Lee; Hyo Jeong Jang; You Jin Choi; Hyun Jin Kim
Journal:  J Korean Med Sci       Date:  2021-05-24       Impact factor: 2.153

3.  Increased Hepatic Fat Content in Patients with Resistance to Thyroid Hormone Beta.

Authors:  Carolina Chaves; Eveline Bruinstroop; Samuel Refetoff; Paul M Yen; João Anselmo
Journal:  Thyroid       Date:  2021-02-19       Impact factor: 6.506

4.  Effect of TSH on Non-Alcoholic Fatty Liver Disease (NAFLD) independent of obesity in children of predominantly Hispanic/Latino ancestry by causal mediation analysis.

Authors:  Presley H Nichols; Yue Pan; Benjamin May; Martina Pavlicova; John C Rausch; Ali A Mencin; Vidhu V Thaker
Journal:  PLoS One       Date:  2020-06-22       Impact factor: 3.240

5.  Reduced expression of thyroid hormone receptor β in human nonalcoholic steatohepatitis.

Authors:  Christin Krause; Martina Grohs; Alexander T El Gammal; Stefan Wolter; Hendrik Lehnert; Oliver Mann; Jens Mittag; Henriette Kirchner
Journal:  Endocr Connect       Date:  2018-12       Impact factor: 3.335

6.  Hepatic steatosis in patients with acromegaly.

Authors:  Andreani Koutsou-Tassopoulou; Ifigeneia Papapostoli-Sklavounou; Marcin Krawczyk; Bettina Friesenhahn-Ochs; Susanne N Weber; Frank Lammert; Caroline S Stokes
Journal:  Endocrinol Diabetes Metab       Date:  2019-08-22

7.  Exploring the Causality Between Hypothyroidism and Non-alcoholic Fatty Liver: A Mendelian Randomization Study.

Authors:  Shizheng Qiu; Peigang Cao; Yu Guo; Haoyu Lu; Yang Hu
Journal:  Front Cell Dev Biol       Date:  2021-03-15

Review 8.  Nonalcoholic Fatty Liver Disease and Hypercholesterolemia: Roles of Thyroid Hormones, Metabolites, and Agonists.

Authors:  Rohit A Sinha; Eveline Bruinstroop; Brijesh K Singh; Paul M Yen
Journal:  Thyroid       Date:  2019-09       Impact factor: 6.568

9.  Association between Thyroid Function and Nonalcoholic Fatty Liver Disease in Euthyroid Type 2 Diabetes Patients.

Authors:  Bin Huang; Shengju Yang; Shandong Ye
Journal:  J Diabetes Res       Date:  2020-09-05       Impact factor: 4.011

10.  Risk of Liver Fibrosis According to TSH Levels in Euthyroid Subjects.

Authors:  Alba Martínez-Escudé; Guillem Pera; Lluís Rodríguez; Ingrid Arteaga; Carmen Expósito-Martínez; Pere Torán-Monserrat; Llorenç Caballería
Journal:  J Clin Med       Date:  2021-03-25       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.